Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Chipmos Technologies (IMOS) Cash & Equivalents (2016 - 2025)

Chipmos Technologies' Cash & Equivalents history spans 10 years, with the latest figure at $479.4 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $479.4 million for Q4 2025, up 1.66% from a year ago — trailing twelve months through Dec 2025 was $479.4 million (up 1.66% YoY), and the annual figure for FY2025 was $473.7 million, down 2.37%.
  • Cash & Equivalents for Q4 2025 was $479.4 million at Chipmos Technologies, up from $471.5 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $479.4 million in Q4 2025 to a low of $212.5 million in Q4 2021.
  • The 5-year median for Cash & Equivalents is $388.6 million (2023), against an average of $373.6 million.
  • The sharpest move saw Cash & Equivalents soared 48.67% in 2022, then grew 1.66% in 2025.
  • Year by year, Cash & Equivalents stood at $212.5 million in 2021, then soared by 48.67% to $316.0 million in 2022, then increased by 22.97% to $388.6 million in 2023, then rose by 21.35% to $471.5 million in 2024, then increased by 1.66% to $479.4 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $479.4 million, $471.5 million, and $388.6 million for Q4 2025, Q4 2024, and Q4 2023 respectively.